Global Opioid-Induced Constipation Market 2015-2019
About Opioid-induced Constipation
Opioids are administered to the patients with acute and non-cancer chronic pain. They have several adverse gastrointestinal effects, one of which is opioid-induced constipation. The opioid analgesics produce analgesia by the activation of the mu receptors found in the CNS and PNS. These drugs affect the motility, tone, and contractility of the bowel functions, which results in the delay in the transit of fecal contents. The opioids also cause a reduction in the secretion of digestive enzymes and also cause partial gastroparesis. Some of the common symptoms of opioid-induced constipation are hard and dry stools, painful defecation, bloating, distention and bulged abdomen, feeling lethargic, and loss of appetite. Opioid-induced constipation can be managed by changing lifestyle along with the use of targeted therapies and other OTC and off-label drugs.
Technavio's analysts forecast the global opioid-induced constipation market to grow at a CAGR of 30.18% over the period 2014-2019.
Covered in this Report
This report covers the present scenario and the growth prospects of the global opioid-induced constipation market for 2015-2019. To calculate the market size, the report considers revenue generated from sales of various drugs used in the treatment of opioid-induced constipation, which includes branded drugs, off-label products, and OTC drugs. On the basis of the mechanism of action of drugs, the market is grouped into the following categories:
Technavio Announces the Publication of its Research Report – Global Opioid-Induced Constipation Market 2015-2019
Technavio recognizes the following companies as the key players in the Global Opioid-Induced Constipation Market: AstraZeneca, Takeda Pharmaceutical and Valeant Pharmaceuticals International
Other Prominent Vendors in the market are: Abbott, Bayer, Boehringer Ingelheim, C.B. Fleet, Cosmo Pharmaceuticals, Daewoong, Daiichi Sankyo, GlaxoSmithKline, Ironwood Pharmaceuticals, Johnson & Johnson, Merck, Mundipharma, Nektar Therapeutics, Pfizer, Progenics Pharmaceuticals, Shionogi, SLA Pharma, Sucampo, Synergy Pharmaceuticals and Theravance
Commenting on the report, an analyst from Technavio’s team said: “The market was served by various off-label and OTC therapies to treat the condition. However, in 2008, Relistor, a targeted therapy for treating opioid-induced constipation, was approved by the US FDA and the EMA. This drug is a peripherally acting mu-opioid receptor antagonist and was the first targeted therapy to obtain approval for this indication. Movantik/Moventig, also a peripherally acting mu-opioid receptor antagonist, was approved by the US FDA and the EMA in 2014 and is a targeted therapy for this indication. These drugs reduce the undesirable effects of the opioid analgesics without affecting its analgesic effects. Therefore, these drugs are increasingly becoming the preferred medication to treat opioid-induced constipation.”
According to the report, the low levels of awareness about opioid-induced constipation among patients and the medical fraternity have resulted in the usage of off-label and OTC medications as the treatment options. However, these drugs are only partially successful in treating this condition. The entry of peripherally acting mu-opioid receptor antagonists such as Movantik/Moventig has driven the market significantly. The drug targets the underlying cause of opioid-induced constipation without affecting the analgesic action of the opioid drugs. Therefore, this is increasingly becoming the preferred treatment option for opioid-induced constipation.
Further, the report states that the availability of OTC and off-label drugs restricts the market growth.
AstraZeneca, Takeda Pharmaceutical, Valeant Pharmaceuticals International, Abbott, Bayer, Boehringer Ingelheim, C.B. Fleet, Cosmo Pharmaceuticals, Daewoong, Daiichi Sankyo, GlaxoSmithKline, Ironwood Pharmaceuticals, Johnson & Johnson, Merck, Mundipharma, Nektar Therapeutics, Pfizer, Progenics Pharmaceuticals, Shionogi, SLA Pharma, Sucampo, Synergy Pharmaceuticals, Theravance